Paul N. Mainwaring - Nanotechnology

Author Information

Paul N. Mainwaring is affiliated with the Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia. His research primarily focuses on personalized nanomedicine and bioengineering, leveraging advanced nanotechnology to address complex medical challenges.

Research Contributions

Paul N. Mainwaring has made significant contributions to the field of oncology and nanomedicine. His recent research includes exploring the combination of anti-angiogenics and checkpoint inhibitors for renal cell carcinoma, developing digital single-molecule nanopillar SERS platforms for monitoring immune toxicities in immunotherapy, and investigating the efficacy and safety of apalutamide in prostate cancer treatment. His work has provided valuable insights into the molecular determinants and clinical responses in various cancers, contributing to the advancement of targeted therapies and personalized medicine.

Aliases

P Mainwaring, Paul N. Mainwaring, Paul N Mainwaring, Paul Mainwaring, P N Mainwaring, P. N. Mainwaring, P. Mainwaring

Publication and Citation Metrics

Metric	Value
Total Citations	19,551
h-index	45
Total Papers	187

Publications:

Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?

DOI: 10.3390/cancers14030644

Year: 2022

A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy

DOI: 10.1038/s41467-021-21431-w

Year: 2021

Efficacy and Safety Exposure–Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

DOI: 10.1158/1078-0432.CCR-20-1041

Year: 2020

Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN.

DOI: 10.1200/jco.2020.38.15_suppl.5521

Year: 2020

Apalutamide and Overall Survival in Prostate Cancer.

DOI: 10.1016/j.eururo.2020.08.011

Year: 2020

Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).

DOI: 10.1200/jco.2020.38.15_suppl.5516

Year: 2020

Abstract 5425: Novel molecular subtypes identified in prostate cancer: Results from the SPARTAN study

DOI: 10.1158/1538-7445.am2020-5425

Year: 2020

632P Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT)

DOI: 10.1016/j.annonc.2020.08.891

Year: 2020

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors

DOI: 10.3389/fonc.2020.01349

Year: 2020

The role of circulating tumor DNA testing in breast cancer liquid biopsies: getting ready for prime time

DOI: 10.2217/bmt-2020-0003

Year: 2020

What is Surface Plasmon Resonance (SPR)?

Can Cassandra Integrate with Other Technologies in Nanotechnology?

Why are Immediate Adjustments Necessary?

What is the Future of Carbon Nanomaterials?

How Do Adaptive Nanomaterials Work?

What Are the Key Applications of ELS in Nanotechnology?

What are the Applications of Mechanical Stirring in Nanotechnology?

How to Address Interface Issues?

How Does Nanotechnology Contribute to Stealth Capabilities?

What are the training requirements for employees handling nanomaterials?

Partnered Content Networks

Relevant Topics